Which statement about PCV23 vaccination in children under 2 years is accurate?

Which statement about PCV23 vaccination in children under 2 years is accurate?

• A. Children younger than 2 years have shown poor immunogenicity to PCV23.
• B. PCV33 does not exist.
• C. PCV23 provides life-long immunity for all serotypes.
• D. PCV23 should be given only after age 2.

Answer: (A)

Infants’ immune systems respond differently to polysaccharide vaccines than to conjugate vaccines. Plain pneumococcal polysaccharide vaccines elicit a T-independent B-cell response that is poorly developed in children under 2, leading to weak antibody production and little lasting immune memory. Conjugating the polysaccharide to a protein turns it into a T-cell–dependent antigen, which engages helper T cells, drives class switching to higher-affinity IgG, and creates memory B cells. This makes the immune response in young children robust and durable. Therefore, stating that children younger than 2 years have shown poor immunogenicity to PCV23 is accurate because PCV23 is a polysaccharide vaccine and does not provoke a strong, lasting response in that age group. The other statements are not correct: there is no PCV33 vaccine; no vaccine guarantees life-long immunity against all serotypes; and PCV23 is not universally reserved only for after age 2—infants receive a conjugate pneumococcal vaccine for primary immunization, with PCV23 used in specific situations later on.

Infants’ immune systems respond differently to polysaccharide vaccines than to conjugate vaccines. Plain pneumococcal polysaccharide vaccines elicit a T-independent B-cell response that is poorly developed in children under 2, leading to weak antibody production and little lasting immune memory. Conjugating the polysaccharide to a protein turns it into a T-cell–dependent antigen, which engages helper T cells, drives class switching to higher-affinity IgG, and creates memory B cells. This makes the immune response in young children robust and durable.

Therefore, stating that children younger than 2 years have shown poor immunogenicity to PCV23 is accurate because PCV23 is a polysaccharide vaccine and does not provoke a strong, lasting response in that age group. The other statements are not correct: there is no PCV33 vaccine; no vaccine guarantees life-long immunity against all serotypes; and PCV23 is not universally reserved only for after age 2—infants receive a conjugate pneumococcal vaccine for primary immunization, with PCV23 used in specific situations later on.